No one doubts at this point that personalized medicine is one of the health-related sectors in which technology, research and innovation will play a more important role.
There is no region that is not working, in a more or less advanced way, to equip its health system – the management of which has been transferred to the regional governments – with all wicker needed for this sector to be a benchmark in the medium and long term.
However, not all autonomies follow the same strategy. There are two speeds, that of those who have been benchmarks for a while, who choose to maintain this joint but individual work, and that of those regions that seek to gain potential by creating alliances.
[La plataforma de fabricación celular que lleva a Asturias a un nuevo nivel en el sector de la medicina personalizada]
In the first group we find, obviously, Navarre. Its internationally recognized genomic technology or the opening of Massive sequencing center in the Foral community – the second public center in all of Spain – These are sufficient reasons for the work that the region develops in this sector to be taken into account.
There are other regions that, although not characterized by their prominence in personalized medicine, have boosted their strategies individually. it is the case of Asturiaswhich, as D+I explained a few days ago, formalizes the purchase of a cell manufacturing platform that will enable the research and development of proprietary and personalized medicines.
The fact that these regions work individually This obviously does not mean that they do not have open lines of cooperation with othersother territories.
What is happening – and this is the difference – is this other autonomous communities, with the support of the central government, decided to join forces.
[Tecnología genómica y enfermedades raras: Navarra se vende en Brasil como líder en medicina personalizada]
This week is featured in Castilla-La Mancha research project on biotechnology applied to healthin which seven regions are involved, including Castile-La Mancha and Andalusia, Aragon, Catalonia, Extremadura, Basque Country and Galicia.
This is a unique research project that will help create a national network for personalized medicine.
This project, which bears the title of “Developing tools for diagnosis, prognosis and advanced or targeted therapies in personalized medicine” It is coordinated by the Ministry of Science and Innovation and is part of the additional plans charged to the funds of the Recovery, Transformation and Sustainability Plan.
The Minister of Education, Culture and Sports Rosa Ana Rodríguez emphasized that thanks to this initiative they will develop various research programs “which aim to seek solutions from science to improve the treatment and quality of life of patients suffering from serious diseases”.
Supercomputers, robotics or nanotechnology
It is thus specified that “through this project a large national network of personalized medicine will be created which will allow the treatment of some serious diseases to be adapted to the specific characteristics of each patient, thus achieving more effective treatment with fewer side effects. And Castilla-La Mancha, thanks to this initiative, will be a flagship project in this network”.
For him, Elements such as biomedicine, artificial intelligence, supercomputing, robotics, sensors and nanotechnology will be combined to design and manufacture new diagnostic, prognostic and therapeutic systems and devices.
“The goal is that within two to three years we will have a range of drugs that can help with these treatments,” the adviser assured.
The project covers the importance of “institutional cooperation” and research groups belonging to UCLM participate in it, such as the Associated Neurodeath Unit, Computer Engineering, Faculty of Medicine of Albacete and Faculty of Environmental Sciences and Biochemistry, and SESCAM, University Hospital of Albacete and University Hospital of Toledo.
Castilla-La Mancha also provides patient cohorts (groups of patients who are part of a clinical trial) in two important pathologies: one with persistent COVID and the other with non-alcoholic fatty liver. Additional cohorts are planned for eventual inclusion.
The project has six lines of action: BERM platform (microscopy); Implementation and analysis of databases in precision medicine; Platform for drug screening and analysis of drug-target interactions; Development of biological models of the disease; Development of nanopharmaceuticals (coordinated by Castilla-La Mancha) and advanced therapies and medical robotics. Castilla-la Mancha’s research groups are involved in all lines of action.